price of our Class A common stock as of December 31, 2025 and December 31, 2024. There were no stock options granted for the years ended December 31, 2025, 2024 and 2023, and no stock-based compensation expense from stock options for the years ended December 31, 2025 and 2024. Stock-based compensation expense from stock options for the year ended December 31, 2023 was As of December 31, 2025, there was no unrecognized compensation cost related to stock options granted under the 2017 Stock Plan. There were no stock options that vested for the years ended December 31, 2025 and 2024. The total grant date fair value of stock options that vested for the year ended December 31, 2023 was $1.1 million. The intrinsic value of stock options exercised for the years ended December 31, 2025, 2024, and 2023 was $0.1 million, $1.4 million, and $12.3 million, respectively. In November 2025, our board of directors authorized a stock repurchase program of up to $500.0 million of our Class A common stock. Under this program, we repurchased and retired 29.4 million shares of our Class A common stock for $250.3 million, including costs associated with the repurchases. As of December 31, 2025, the remaining availability under the stock repurchase authorization was $250.0 million. This program was completed in January 2026.